{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:10:47Z","timestamp":1772752247391,"version":"3.50.1"},"reference-count":119,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/crd.0b013e318093e43a","type":"journal-article","created":{"date-parts":[[2007,8,10]],"date-time":"2007-08-10T07:06:51Z","timestamp":1186729611000},"page":"242-256","source":"Crossref","is-referenced-by-count":27,"title":["Direct Inhibition of Renin as a Cardiovascular Pharmacotherapy"],"prefix":"10.1097","volume":"15","author":[{"given":"Reza","family":"Sepehrdad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles T.","family":"Stier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenic A.","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.01201005","article-title":"Direct renin inhibition with aliskiren in hypertension and target organ damage.","volume":"1","author":"M\u00fcller","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.crd.0000195220.62533.c5","article-title":"Chymase: a new pharmacologic target in cardiovascular disease.","volume":"14","author":"Bacani","year":"2006","journal-title":"Cardiol Rev"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts.","volume":"66","author":"Urata","year":"1990","journal-title":"Circ Res"},{"key":"R8-4-20210203","first-page":"207","article-title":"Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents.","volume":"62","author":"Okunishi","year":"1993","journal-title":"Jpn J Pharmacol"},{"issue":"suppl 11","key":"R9-4-20210203","first-page":"S239","article-title":"Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition.","volume":"10","author":"Hollenberg","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(24)37058-2","article-title":"Renin versus angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin.","volume":"283","author":"Allan","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"R11-4-20210203","first-page":"F563","article-title":"Molecular biology of the renin-angiotensin system.","volume":"255","author":"Dzau","year":"1988","journal-title":"Am J Physiol"},{"issue":"suppl 11","key":"R12-4-20210203","first-page":"S162","article-title":"Regulation of renin secretion by angiotensin II-AT1 receptors.","volume":"10","author":"Kurtz","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.80.22.6809","article-title":"Biosynthesis of renin: multiplicity of active and intermediate forms.","volume":"80","author":"Pratt","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1172\/JCI111300","article-title":"Renin biosynthesis by human tumoral juxtaglomerular cells. Evidences for a renin precursor.","volume":"73","author":"Galen","year":"1984","journal-title":"J Clin Invest"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.16.1.1","article-title":"Human renin inhibitor peptides.","volume":"16","author":"Corvol","year":"1990","journal-title":"Hypertension"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/357466a0","article-title":"X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins.","volume":"357","author":"Dhanaraj","year":"1992","journal-title":"Nature"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.ki.5000079","article-title":"Receptor-mediated actions of renin and prorenin.","volume":"69","author":"Oliver","year":"2006","journal-title":"Kidney Int"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0895-7061(96)00092-1","article-title":"Specific prorenin\/renin binding (ProfBP). Identification and characterization of a novel membrane site.","volume":"9","author":"Sealey","year":"1996","journal-title":"Am J Hypertens"},{"issue":"5","key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ajh\/2.5.403","article-title":"Regulation of angiotensinogen gene.","volume":"2","author":"Clauser","year":"1989","journal-title":"Am J Hypertens"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0006-291X(81)90762-2","article-title":"The amino terminal amino acid sequence of human angiotensinogen.","volume":"99","author":"Tewksbury","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1021\/bi00311a006","article-title":"Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence.","volume":"23","author":"Kageyama","year":"1984","journal-title":"Biochemistry"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/01.HYP.0000221065.05670.23","article-title":"Angiotensinogen modulates renal vasculature growth.","volume":"47","author":"Brand","year":"2006","journal-title":"Hypertension"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/01.HYP.38.2.243","article-title":"Renin uptake by the endothelium mediates vascular angiotensin formation.","volume":"38","author":"Hilgers","year":"2001","journal-title":"Hypertension"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-6147(00)01994-5","article-title":"The angiotensin-converting enzyme gene family: genomics and pharmacology.","volume":"23","author":"Turner","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1043-2760(99)00156-3","article-title":"Potentiation of bradykinin actions by ACE inhibitors.","volume":"10","author":"Erdos","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"R26-4-20210203","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/cs1000481","article-title":"Angiotensin receptors: distribution, signalling and function.","volume":"100","author":"Dinh","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1091\/mbc.1.9.649","article-title":"Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function.","volume":"1","author":"Hahn","year":"1990","journal-title":"Cell Regul"},{"key":"R28-4-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.jhh.1000635","article-title":"Molecular and cellular mechanisms of action of angiotensin II (AT1) receptors in vascular smooth muscle.","volume":"12","author":"Hughes","year":"1998","journal-title":"J Hum Hypertens"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4899-1376-0_11","article-title":"Regulation of the hypothalamic-pituitary-adrenal axis and vasopressin secretion. Role of angiotensin II.","volume":"396","author":"Aguilera","year":"1996","journal-title":"Adv Exp Med Biol"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10641969509087071","article-title":"Angiotensin as neuromodulator\/neurotransmitter in central control of body fluid and electrolyte homeostasis.","volume":"17","author":"Culman","year":"1995","journal-title":"Clin Exp Hypertens"},{"issue":"suppl 6","key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/00005344-199219006-00013","article-title":"Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems.","volume":"19","author":"Saxena","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"suppl 3","key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199000153-00001","article-title":"The renin-angiotensin system: importance in physiology and pathology.","volume":"15","author":"Ferrario","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"R33-4-20210203","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.37.2.710","article-title":"Cardiomyocytes bind and activate native human prorenin: role of soluble mannose 6-phosphate receptors.","volume":"7","author":"Saris","year":"2001","journal-title":"Hypertension"},{"key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1476-5381.1996.tb15277.x","article-title":"Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.","volume":"117","author":"van Kats","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"1","key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1067\/mhj.2000.102901","article-title":"Neurohormonal modulation in cardiovascular disease.","volume":"139","author":"Unger","year":"2000","journal-title":"Am Heart J"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1073\/pnas.97.2.931","article-title":"Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.","volume":"97","author":"Paradis","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/01.HYP.33.1.389","article-title":"Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension.","volume":"33","author":"Mervaala","year":"1999","journal-title":"Hypertension"},{"issue":"suppl 11","key":"R38-4-20210203","first-page":"S23","article-title":"Localization of angiotensin AT1 and AT2 receptors.","volume":"10","author":"Allen","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R39-4-20210203","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9440(10)64571-3","article-title":"Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study.","volume":"157","author":"Busche","year":"2000","journal-title":"Am J Pathol"},{"key":"R40-4-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/01.HYP.32.1.78","article-title":"Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart.","volume":"32","author":"Wang","year":"1998","journal-title":"Hypertension"},{"key":"R41-4-20210203","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.103.058420","article-title":"Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload.","volume":"30","author":"Yayama","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R42-4-20210203","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI117710","article-title":"The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells.","volume":"95","author":"Stoll","year":"1995","journal-title":"J Clin Invest"},{"key":"R43-4-20210203","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1073\/pnas.92.23.10663","article-title":"The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer.","volume":"92","author":"Nakajima","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R44-4-20210203","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1073\/pnas.93.1.156","article-title":"Angiotensin II type 2 receptor mediates programmed cell death.","volume":"93","author":"Yamada","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"R45-4-20210203","doi-asserted-by":"crossref","first-page":"L289","DOI":"10.1016\/S0024-3205(98)00448-2","article-title":"Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study.","volume":"63","author":"Yamada","year":"1998","journal-title":"Life Sci"},{"key":"R46-4-20210203","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.hco.0000166596.44711.b4","article-title":"Angiotensin type-2 receptors and cardiovascular function: are angiotensin type-2 receptors protective?","volume":"20","author":"Carey","year":"2005","journal-title":"Curr Opin Cardiol"},{"key":"R47-4-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.HYP.0000050101.90932.14","article-title":"Cardiac angiotensin II type 2 receptor activates the kinin\/NO system and inhibits fibrosis.","volume":"41","author":"Kurisu","year":"2003","journal-title":"Hypertension"},{"key":"R48-4-20210203","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.HYP.0000127563.14064.fd","article-title":"Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer.","volume":"43","author":"Metcalfe","year":"2004","journal-title":"Hypertension"},{"key":"R49-4-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/01.CIR.104.3.346","article-title":"Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension.","volume":"104","author":"Ichihara","year":"2001","journal-title":"Circulation"},{"key":"R50-4-20210203","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1161\/01.HYP.0000193504.51489.cf","article-title":"The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.","volume":"46","author":"D'Amore","year":"2005","journal-title":"Hypertension"},{"key":"R51-4-20210203","first-page":"589","article-title":"Cardiovascular Pharmacotherapeutics. 2nd ed.","author":"Frishman","year":"2003"},{"key":"R52-4-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1084\/jem.119.3.425","article-title":"Production of antirenin to homologous renin and its effect of experimental renal hypertension.","volume":"119","author":"Deodhar","year":"1964","journal-title":"J Exp Med"},{"issue":"4","key":"R53-4-20210203","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/01.CIR.17.4.648","article-title":"Studies on renin antibodies.","volume":"17","author":"Helmer","year":"1958","journal-title":"Circulation"},{"key":"R54-4-20210203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.6986653","article-title":"Renin-specific antibody for study of cardiovascular homeostasis.","volume":"207","author":"Dzau","year":"1980","journal-title":"Science"},{"key":"R55-4-20210203","first-page":"1467","article-title":"Effects of chronic administration of a monoclonal antibody against human renin in the marmoset.","volume":"9","author":"Wood","year":"1987","journal-title":"Clin Exp Hypertens"},{"key":"R56-4-20210203","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/01.HYP.8.7.600","article-title":"Monoclonal antibodies against human renin. Blood pressure effects in the marmoset.","volume":"8","author":"Wood","year":"1986","journal-title":"Hypertension"},{"key":"R57-4-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1073\/pnas.81.1.48","article-title":"Synthesis of peptides related to the prosegment of mouse submaxillary gland renin precursor: an approach to renin inhibitors.","volume":"81","author":"Evin","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"R58-4-20210203","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1016\/S0021-9258(17)39344-4","article-title":"Inhibition of human renin by synthetic peptides derived from its prosegment.","volume":"260","author":"Cumin","year":"1985","journal-title":"J Biol Chem"},{"key":"R59-4-20210203","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7164\/antibiotics.24.687","article-title":"Effect of pepstatin on acid proteases.","volume":"24","author":"Aoyagi","year":"1971","journal-title":"J Antibiot (Tokyo)"},{"key":"R60-4-20210203","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.175.4022.656","article-title":"Inhibition of the renin-angiotensinogen reaction by pepstatin.","volume":"175","author":"Gross","year":"1972","journal-title":"Science"},{"key":"R61-4-20210203","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/0006-2952(72)90221-3","article-title":"Renin inhibition by pepstatin.","volume":"21","author":"Miller","year":"1972","journal-title":"Biochem Pharmacol"},{"key":"R62-4-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/303081a0","article-title":"Novel renin inhibitors containing the amino acid statine.","volume":"303","author":"Boger","year":"1983","journal-title":"Nature"},{"key":"R63-4-20210203","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/jm00157a006","article-title":"Pepstatin analogues as novel renin inhibitors.","volume":"29","author":"Guegan","year":"1986","journal-title":"J Med Chem"},{"key":"R64-4-20210203","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1021\/bi00334a014","article-title":"Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.","volume":"24","author":"Rich","year":"1985","journal-title":"Biochemistry"},{"key":"R65-4-20210203","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/217456a0","article-title":"Peptide inhibitors of the renin-angiotensin system.","volume":"217","author":"Kokubu","year":"1968","journal-title":"Nature"},{"key":"R66-4-20210203","first-page":"135","article-title":"Competitive inhibitors of renin.","volume":"12","author":"Poulsen","year":"1976","journal-title":"Biochemistry"},{"key":"R67-4-20210203","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1073\/pnas.77.9.5476","article-title":"Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renin-dependent hypertension.","volume":"77","author":"Burton","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"R68-4-20210203","first-page":"365","article-title":"Hemodynamic effects of a competitive renin inhibitory peptide in humans: evidence for multiple mechanisms of action.","volume":"96","author":"Zusman","year":"1983","journal-title":"Trans Assoc Am Physicians"},{"key":"R69-4-20210203","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/299555a0","article-title":"Potent new inhibitors of human renin.","volume":"299","author":"Szelke","year":"1982","journal-title":"Nature"},{"issue":"6","key":"R70-4-20210203","first-page":"II1","article-title":"Statine-containing dipeptide and tripeptide inhibitors of human renin.","volume":"8","author":"Kokubu","year":"1986","journal-title":"Hypertension"},{"issue":"suppl 7","key":"R71-4-20210203","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1097\/00005344-198706107-00014","article-title":"In vitro inhibition of human renin by statine-containing tripeptide renin inhibitor (ES-1005).","volume":"10","author":"Kokubu","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"key":"R72-4-20210203","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/jm00393a029","article-title":"Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini.","volume":"30","author":"Bock","year":"1987","journal-title":"J Med Chem"},{"key":"R73-4-20210203","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jm00399a001","article-title":"New human renin inhibitors containing an unnatural amino acid, norstatine.","volume":"31","author":"Iizuka","year":"1988","journal-title":"J Med Chem"},{"key":"R74-4-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0014-2999(86)90455-3","article-title":"Human renin inhibiting dipeptide.","volume":"129","author":"Toda","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"R75-4-20210203","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1021\/jm00149a001","article-title":"Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.","volume":"28","author":"Thaisrivongs","year":"1985","journal-title":"J Med Chem"},{"key":"R76-4-20210203","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1021\/jm00160a048","article-title":"Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.","volume":"29","author":"Thaisrivongs","year":"1986","journal-title":"J Med Chem"},{"key":"R77-4-20210203","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/jm00150a007","article-title":"Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.","volume":"28","author":"Boger","year":"1985","journal-title":"J Med Chem"},{"key":"R78-4-20210203","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1021\/jm00394a035","article-title":"Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.","volume":"30","author":"Dellaria","year":"1987","journal-title":"J Med Chem"},{"key":"R79-4-20210203","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1021\/jm00117a003","article-title":"Design of rat renin inhibitory peptides.","volume":"31","author":"Hui","year":"1988","journal-title":"J Med Chem"},{"issue":"6","key":"R80-4-20210203","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/01.HYP.11.6.708","article-title":"A highly potent and long-acting oral inhibitor of human renin.","volume":"11","author":"Hiwada","year":"1988","journal-title":"Hypertension"},{"key":"R81-4-20210203","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1021\/jm00120a005","article-title":"Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.","volume":"31","author":"Luly","year":"1988","journal-title":"J Med Chem"},{"key":"R82-4-20210203","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(88)80637-9","article-title":"Renin inhibitors. Improvements in the stability and biological activity of small peptides containing novel Leu-Val replacements.","volume":"230","author":"Kleinert","year":"1988","journal-title":"FEBS Lett"},{"key":"R83-4-20210203","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1021\/jm00394a008","article-title":"Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.","volume":"30","author":"Kempf","year":"1987","journal-title":"J Med Chem"},{"key":"R84-4-20210203","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1021\/jm00127a041","article-title":"Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond.","volume":"32","author":"Allen","year":"1989","journal-title":"J Med Chem"},{"key":"R85-4-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1073\/pnas.81.1.48","article-title":"Synthesis of peptides related to the prosegment of mouse submaxillary gland renin precursor: an approach to renin inhibitors.","volume":"81","author":"Evin","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"R86-4-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/jm00396a006","article-title":"Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1\u2032 Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.","volume":"31","author":"Sawyer","year":"1988","journal-title":"J Med Chem"},{"issue":"suppl 7","key":"R87-4-20210203","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/00005344-198706107-00009","article-title":"Renin inhibitors: a search for principles of design.","volume":"10","author":"Haber","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"key":"R88-4-20210203","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/jm00118a009","article-title":"Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency.","volume":"31","author":"Bock","year":"1988","journal-title":"J Med Chem"},{"issue":"suppl 4","key":"R89-4-20210203","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/00005344-199016004-00016","article-title":"Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.","volume":"16","author":"Glassman","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"R90-4-20210203","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1248\/cpb.50.850","article-title":"New renin inhibitors with pseudodipeptidic units in P(1)-P(1\u2032) and P(2\u2032)-P(3\u2032) positions.","volume":"50","author":"Paruszewski","year":"2002","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"R91-4-20210203","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2125.1989.tb03421.x","article-title":"Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers.","volume":"27","author":"de Gasparo","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"R92-4-20210203","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1021\/jm00088a007","article-title":"C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.","volume":"35","author":"Boyd","year":"1992","journal-title":"J Med Chem"},{"key":"R93-4-20210203","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor.","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R94-4-20210203","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin.","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem Biol"},{"key":"R95-4-20210203","first-page":"E1","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril.","volume":"39","author":"Nussberger","year":"2003","journal-title":"Hypertension"},{"key":"R96-4-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","article-title":"Renin inhibition with aliskiren: where are we now and where are we going?","volume":"24","author":"Azizi","year":"2006","journal-title":"J Hypertens"},{"key":"R97-4-20210203","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270006294404","article-title":"Pharmacokinetics, safety and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment.","volume":"47","author":"Vaidyanathan","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R98-4-20210203","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003088-200645110-00006","article-title":"Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.","volume":"45","author":"Zhao","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R99-4-20210203","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"issue":"suppl","key":"R100-4-20210203","first-page":"797","article-title":"Aliskiren, an oral renin inhibitor, provides long-term antihypertensive efficacy and safety in patients with hypertension.","volume":"27","author":"Sica","year":"2006","journal-title":"Eur Heart J"},{"issue":"suppl A","key":"R101-4-20210203","first-page":"A80","article-title":"Renal localization of the renin inhibitor aliskiren [abstract].","volume":"8","author":"Feldman","year":"2006","journal-title":"J Clin Hypertens"},{"issue":"suppl A","key":"R102-4-20210203","first-page":"A86","article-title":"The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal [abstract].","volume":"8","author":"Herron","year":"2006","journal-title":"J Clin Hypertens"},{"key":"R103-4-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004872-200502000-00025","article-title":"Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.","volume":"23","author":"Wood","year":"2005","journal-title":"J Hypertens"},{"key":"R104-4-20210203","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179573.91016.3f","article-title":"Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.","volume":"46","author":"Pilz","year":"2005","journal-title":"Hypertension"},{"key":"R105A-4-20210203","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.","volume":"49","author":"Oh","year":"2007","journal-title":"J AM Coll Cardiol"},{"key":"R106-4-20210203","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"R107-4-20210203","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"R108-4-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.","volume":"20","author":"Pool","year":"2007","journal-title":"Am J Hypertens"},{"issue":"suppl 6","key":"R109-4-20210203","first-page":"99","article-title":"The oral renin inhibitor aliskiren has comparable safety and efficacy to lisinopril in patients with severe hypertension [abstract].","volume":"24","author":"Strasser","year":"2006","journal-title":"J Hypertens"},{"key":"R111-4-20210203","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","article-title":"Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.","volume":"15","author":"Azizi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R113-4-20210203","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.","volume":"25","author":"Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"R113A-4-20210203","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct renin inhibition with aliskiren in obese patients with arterial hypertension.","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"R115-4-20210203","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"R115A-4-20210203","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjhyper.2007.04.001","article-title":"Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.","volume":"20","author":"Sealey","year":"2007","journal-title":"Am J Hypertens"},{"key":"R116-4-20210203","first-page":"29","article-title":"Aliskiren (Tekturna) for hypertension.","volume":"49","year":"2007","journal-title":"Med Lett Drugs Ther"},{"key":"R117-4-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02160.x","article-title":"Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.","volume":"58","author":"Dieterle","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R118-4-20210203","doi-asserted-by":"crossref","first-page":"527","DOI":"10.5414\/CPP43527","article-title":"Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.","volume":"43","author":"Dieterle","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R119-4-20210203","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0091270006297921","article-title":"Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.","volume":"47","author":"Vaidyanathan","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R120-4-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors.","volume":"368","author":"Staessen","year":"2006","journal-title":"Lancet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045415-200709000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:18:22Z","timestamp":1737357502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-200709000-00004"}},"subtitle":["Focus on Aliskiren"],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e318093e43a","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}